Ian F. Pollack, MD

  • A. Leland Albright Distinguished Professor
  • Vice Chair, Academic Affairs
  • Chief, Pediatric Neurosurgery, UPMC Children's Hospital of Pittsburgh
  • Co-Director, Neurosurgical Oncology
  • Professor of Clinical and Translational Science

Ian Pollack, MD, is chief of pediatric neurosurgery at UPMC Children’s Hospital of Pittsburgh, A. Leland Albright Professor of Neurosurgery at the University of Pittsburgh School of Medicine, and co-director of the Neurosurgical Oncology Program at the Hillman Cancer Institute.

Prior to joining the faculty of the Department of Neurological Surgery at the University of Pittsburgh in 1992, he was awarded the 1991 Van Wagenen Traveling Fellowship, which afforded him a year of subspecialty training in the Department of Neurosurgery at the Hospital for Sick Children in Toronto, the Neuro-Oncology Laboratory of the University of Lausanne in Switzerland, and the Laboratory of Tumor Biology of the University of Uppsala in Sweden.

Dr. Pollack graduated magna cum laude from Emory University in 1980, where he earned a BS degree in chemistry. He received his medical degree from the Johns Hopkins University School of Medicine in 1984, then completed a surgical internship and neurosurgical residency at the University of Pittsburgh School of Medicine. He also was a research fellow in neuropathology and neurobiology during some of that time.

Dr. Pollack has published more than 380 papers in refereed journals, numerous book chapters and invited papers, and has edited three books on childhood brain tumors. He is co-editor of the book Principles and Practice of Pediatric Neurosurgery—currently in its third edition—and an accompanying atlas Operative Techniques In Pediatric Neurosurgery as well as Brain and Spinal Tumors of Childhood, a multinational state-of-the-art text.

He is currently a principal investigator on NIH grants focusing on novel therapies for brain tumors, including immunotherapy in childhood brain tumors. Dr. Pollack was named vice chair of academic affairs for the department in July of 2008.

He also chaired the Children’s Oncology Group CNS Tumor Committee from 1999-2009, and co-chaired the National Cancer Institute Brain Malignancy Steering Committee between 2010 and 2017. He is currently chair of the American Board of Pediatric Neurosurgery and a director on the Accreditation Council for Pediatric Neurosurgery Fellowships.

Dr. Pollack's publications can be reviewed through the National Library of Medicine's publication database.

Specialized Areas of Interest

Pediatric neurosurgery; pediatric neuro-oncology; craniofacial surgery; congenital spinal abnormalities; brain tumor clinical trials.

Board Certifications

American Board of Neurological Surgery
American Board of Pediatric Neurosurgery

Hospital Privileges

UPMC Children's Hospital of Pittsburgh
UPMC Magee-Women's Hospital
UPMC Presbyterian

Professional Organization Membership

Academy of Neurological Surgeons
Alpha Omega Alpha
American Academy of Pediatrics
American Association for the Advancement of Science
American Association for Cancer Research
American Association of Neurological Surgeons (AANS)
American College of Surgeons
American Society for Pediatric Neurosurgery
American Society for Clinical Investigation
Association of American Physicians
Children's Oncology Group
Congress of Neurological Surgeons
John Hopkins Medical and Surgical Society
Joint Section on Tumors (AANS/CNS)
Phi Beta Kappa
Society of Neurological Surgeons
Society for Neuro-Oncology
Society of Surgical Oncology

Professional Activities

Institutional PI, Pediatric Brain Tumor Consortium
Steering Committee, Pediatric Brain Tumor Consortium
Executive Committee, Pediatric Brain Tumor Consortium
Chair, Translational Biology Committee, Pediatric Brain Tumor Consortium
Institutional PI, Hydrocephalus Clinical Research Network
Institutional PI, Synostosis Research Group
Vice-Chair, American Board of Pediatric Neurological Surgery
Director, Accreditation Council for Pediatric Neurosurgery Fellowships

Education & Training

  • BS, Chemistry, Emory University, Magna cum Laude, 1980
  • MD, Johns Hopkins University School of Medicine, 1984
  • Fellowship, University of Pittsburgh, 1990
  • Residency, University of Pittsburgh, 1991
  • Fellowship, Hospital for Sick Children, 1991
  • Fellowship, University of Lausanne, 1991
  • Fellowship, University of Uppsala, 1992

Honors & Awards

  • Pittsburgh’s Best Doctors, Pittsburgh Magazine, 2012-21
  • Joan Venes Lectureship, University of Michigan, 2019
  • Albert Nelson Marquis Lifetime Achievement Award, Marquis Who’s Who, 2018
  • Castle Connolly’s America’s Top Doctors, 2002-20
  • Who’s Who in America, Marquis, 2005-20
  • Who’s Who in the World, Marquis, 2008-20
  • Castle Connolly’s America’s Top Cancer Doctors, 2005-20
  • Certificate of Appreciation for BMSC Co-chairship, National Cancer Institute, 2017
  • E. Bruce Hendrick Visiting Professor in Pediatric Neurosurgery, University of Toronto, 2016
  • Columbia Softball Charity Award, American Association of Neurological Surgeons Annual Meeting, 2016
  • Children’s Brain Tumor Foundation, Award for Scientific Excellence, 2016
  • Winn Prize, Society of Neurological Surgeons, 2015
  • Van Wagenen Lecturer, American Association of Neurological Surgeons Annual Meeting, 2014

Research Activities

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance

Dr. Pollack’s group has continued to build on their recent studies designed to define the mechanisms underlying resistance in childhood and adult malignant gliomas. For these efforts, they have developed a series of “drug-resistance” tumor model systems, paired with treatment naïve counterparts. They have leveraged this unique resource to built a strong collaboration with the Drug Discovery Institute and the Systems Biology Program, through which they have characterized the NAD metabolic pathway as a key intermediate through which multiple cell lines achieve treatment resistance. Using RNA sequencing studies and pathway analysis they have identified several common molecular drivers of this process as well as downstream signaling pathways that are hijacked to promote a resistance phenotype. These observations have provided a basis for additional studies that examine pharmacological and RNA interference-based strategies for reversing resistance as well as metabolic manipulations that may provide novel approaches for promoting tumor cell killing. Planned studies will also examine whether the resistance phenotype reflects clonal selection or an epitranscriptomic phenomenon, which will have implications for how best to counteract this common process to achieve durable responses.

This project has been supported by The Cure Starts Now Foundation, The Cure Starts Now Australia, Brooke Healey Foundation, Aidan's Avengers, Aubreigh’s Army Foundation 328, Cure Brain Cancer, Jeffrey Thomas Hayden Foundation, Laurie’s Love Foundation, Melina Michelle Edenfield Foundation, Musella Foundation, Pray Hope Believe, Reflections Of Grace, RUN DIPG, Storm the Heavens Fund, Wayland Villars Foundation, Whitley’s Wishes, The Gold Hope Project, Love Chloe Foundation, The Isabella and Marcus Foundation, Lauren's Fight for Cure, Robert Connor Dawes Foundation, American Childhood Cancer Organization, Lily Larue Foundation, Marlee’s Mission, Ryan's Hope, The DIPG Collaborative, and Snapgrant.com.

Preliminary data for this work has also been funded by a grant from the Children’s Neuroscience Institute of the University of Pittsburgh, the Connor’s Cure Fund of the V Foundation, the Translational Brain Tumor Research Fund and the DIPG Research Fund of the Children’s Hospital of Pittsburgh Foundation.

NIH-Funded Brain Tumor Vaccine Studies

Dr. Pollack’s group has also continued their NIH-funded activities that focus on immunotherapy for pediatric brain tumors. They have applied RNA sequencing of peripheral blood mononuclear cells in their low-grade glioma cohort to characterize gene expression patterns associated with favorable response to vaccine therapy, and those associated with resistance to therapy. They are working to counteract the latter in preclinical therapeutic studies. Accrual continues on their ongoing clinical trials for recurrent low-grade gliomas and ependymomas.

Media Appearances

Fall 2014
UPMC Cancer Center 2014 Annual Report

Glioma: Pilot Trial Shows Peptide Vaccine Active in Pediatric Patients
May 25, 2012
Oncology Times

First-of-its-kind Study of Peptide Vaccine by Pittsburgh Researchers Shows Evidence of Immunological Response in Children with Gliomas
April 4, 2012

Study Suggests Vaccine May Help Kids With Brain Cancer
April 3, 2012
U.S. News and World Report Health Day

Study Suggests Vaccine May Help Kids With Brain Cancer
April 3, 2012

Study Suggests Vaccine May Help Kids With Brain Cancer
April 3, 2012
MSN Health

Peptide vaccine shows evidence of immunological, clinical activity in children with gliomas
April 3, 2012

Brain Tumor Vaccine for Children
April 2, 2012
WTAJ-TV (Johnstown)

Teen Has New Lease On Life After Brain Tumor Removal 
July 22, 2009
WTAE TV-4 (Pittsburgh) Evening News

Study finds clue to deadly childhood brain cancers
February 7, 2002
Pittsburgh Post-Gazette

UPMC On Topic Videos

Brain Care Institute: Expertise
Dr. Pollack talks about managing many of the unusual types of brain tumors.

Brain Care Institute: A Top-Notch Institution
Dr. Pollack talks about the advantages afforded by working at Children's Hospital of Pittsburgh.

Brain Care Institute: A Rewarding Experience
Dr. Pollack talks about the experiences that give him a great sense of satisfaction in his work.